ArticleBMC ophthalmology2026
Predictive factors, timing, and management of recurrent vitreous hemorrhage after pars plana vitrectomy in advanced proliferative diabetic retinopathy.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the incidence, timing, predictive factors, pathophysiological mechanisms, and management outcomes of recurrent vitreous hemorrhage (RVH) following pars plana vitrectomy (PPV) in patients with advanced proliferative diabetic retinopathy (PDR), and to contextualize these findings within the current literature.
methodsThis retrospective cohort study included 65 patients undergoing 25-gauge PPV for vitreous hemorrhage secondary to PDR with a mean follow-up of 15 ± 3 months. All patients received preoperative anti-VEGF injection 5 days prior to surgery. Demographic, systemic, ocular, and intraoperative variables were analyzed. Recurrent vitreous hemorrhage was classified as early (< 4 weeks) or late (> 4 weeks). Comparative univariate analyses were performed to identify factors associated with RVH.
resultsRecurrent vitreous hemorrhage developed in 13 of 65 patients (20.0%). Early RVH occurred in 11 patients (16.9%), whereas late RVH occurred in 2 patients (3.1%). Severe intraoperative bleeding (38.5% vs. 0%, p < 0.001), anticoagulant use (53.8% vs. 25.0%, p = 0.04), and dialysis (38.5% vs. 9.6%, p = 0.01) were significantly associated with RVH. Silicone oil tamponade was less frequently used in patients who developed RVH (23.1% vs. 65.4%, p = 0.01). Tractional retinal detachment was not significantly associated with RVH (p = 0.78).
conclusionRecurrent vitreous hemorrhage remains a clinically significant complication following PPV in advanced PDR. Severe intraoperative bleeding, anticoagulant use, and dialysis were significantly associated with RVH development, whereas silicone oil tamponade was associated with a lower frequency of postoperative hemorrhage. These findings may contribute to risk stratification and postoperative monitoring in patients with advanced PDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.